New treatment strategies for uterine sarcoma using secreted frizzled ‑related proteins
In conclusion, SFRP4 may suppress the viability and migration, and enhance the adhesion of sarcoma cells. These results suggested that SFRP4 could be considered as a novel therapeutic target for uterine sarcoma.PMID:38628655 | PMC:PMC11019650 | DOI:10.3892/etm.2024.12520 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - April 17, 2024 Category: General Medicine Authors: Tomohiro Kagawa Ayuka Mineda Tomotaka Nakagawa Ayaka Shinohara Ryosuke Arakaki Hiroaki Inui Hiroki Noguchi Atsuko Yoshida Riyo Kinouchi Yuri Yamamoto Kanako Yoshida Takashi Kaji Masato Nishimura Takeshi Iwasa Source Type: research
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma
CONCLUSION: FGF23 was highly expressed in US and was promising as a novel potential biomarker for the diagnosis and prognosis of US.PMID:38613349 | DOI:10.1177/15330338241245924 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - April 13, 2024 Category: Cancer & Oncology Authors: Ling Yang Ying Cai Yunjia Wang Yue Huang Chi Zhang Hu Ma Jian-Guo Zhou Source Type: research
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma
CONCLUSION: FGF23 was highly expressed in US and was promising as a novel potential biomarker for the diagnosis and prognosis of US.PMID:38613349 | PMC:PMC11015760 | DOI:10.1177/15330338241245924 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - April 13, 2024 Category: Cancer & Oncology Authors: Ling Yang Ying Cai Yunjia Wang Yue Huang Chi Zhang Hu Ma Jian-Guo Zhou Source Type: research
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma
CONCLUSION: FGF23 was highly expressed in US and was promising as a novel potential biomarker for the diagnosis and prognosis of US.PMID:38613349 | PMC:PMC11015760 | DOI:10.1177/15330338241245924 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - April 13, 2024 Category: Cancer & Oncology Authors: Ling Yang Ying Cai Yunjia Wang Yue Huang Chi Zhang Hu Ma Jian-Guo Zhou Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Biochimica et Biophysica Acta - April 5, 2024 Category: Biochemistry Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Biochimica et Biophysica Acta - April 5, 2024 Category: Biochemistry Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells
Biochim Biophys Acta Mol Cell Res. 2024 Apr 3:119721. doi: 10.1016/j.bbamcr.2024.119721. Online ahead of print.ABSTRACTMetabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation o...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Katharina Huber Albert Giralt Ren é Dreos Helene Michenthaler Sarah Geller Valentin Barquissau Dorian V Ziegler Daniele Tavernari Hector Gallart-Ayala Katarina Krajina Katharina Jonas Giovanni Ciriello Julijana Ivanisevic Andreas Prokesch Martin Pichler Source Type: research
The Spectrum of Fusions Occurring in Non-Smooth Muscle Mesenchymal Uterine Tumors: A Review of the Current Knowledge
CONCLUSIONS.—: One hundred ten fusions were identified in 703 tumors. The diagnostic significance of the molecular aberrations occurring in these tumors can be unclear in some cases. This can be related to the rare aberrations with a limited number of reported cases. Additionally, even well-known aberrations considered as specific for a certain distinct entity can occur in more lesions, the biological behavior and clinical significance of which can differ substantially.PMID:38484759 | DOI:10.5858/arpa.2023-0324-RA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - March 14, 2024 Category: Laboratory Medicine Authors: Pavel Dundr Radoslav Mat ěj Jan Hojn ý Nikola H ájková Krist ýna Němejcová Michaela Kendall B ártů Source Type: research
The Spectrum of Fusions Occurring in Non-Smooth Muscle Mesenchymal Uterine Tumors: A Review of the Current Knowledge
CONCLUSIONS.—: One hundred ten fusions were identified in 703 tumors. The diagnostic significance of the molecular aberrations occurring in these tumors can be unclear in some cases. This can be related to the rare aberrations with a limited number of reported cases. Additionally, even well-known aberrations considered as specific for a certain distinct entity can occur in more lesions, the biological behavior and clinical significance of which can differ substantially.PMID:38484759 | DOI:10.5858/arpa.2023-0324-RA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - March 14, 2024 Category: Laboratory Medicine Authors: Pavel Dundr Radoslav Mat ěj Jan Hojn ý Nikola H ájková Krist ýna Němejcová Michaela Kendall B ártů Source Type: research
The Spectrum of Fusions Occurring in Non-Smooth Muscle Mesenchymal Uterine Tumors: A Review of the Current Knowledge
CONCLUSIONS.—: One hundred ten fusions were identified in 703 tumors. The diagnostic significance of the molecular aberrations occurring in these tumors can be unclear in some cases. This can be related to the rare aberrations with a limited number of reported cases. Additionally, even well-known aberrations considered as specific for a certain distinct entity can occur in more lesions, the biological behavior and clinical significance of which can differ substantially.PMID:38484759 | DOI:10.5858/arpa.2023-0324-RA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - March 14, 2024 Category: Laboratory Medicine Authors: Pavel Dundr Radoslav Mat ěj Jan Hojn ý Nikola H ájková Krist ýna Němejcová Michaela Kendall B ártů Source Type: research
The Spectrum of Fusions Occurring in Non-Smooth Muscle Mesenchymal Uterine Tumors: A Review of the Current Knowledge
CONCLUSIONS.—: One hundred ten fusions were identified in 703 tumors. The diagnostic significance of the molecular aberrations occurring in these tumors can be unclear in some cases. This can be related to the rare aberrations with a limited number of reported cases. Additionally, even well-known aberrations considered as specific for a certain distinct entity can occur in more lesions, the biological behavior and clinical significance of which can differ substantially.PMID:38484759 | DOI:10.5858/arpa.2023-0324-RA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - March 14, 2024 Category: Laboratory Medicine Authors: Pavel Dundr Radoslav Mat ěj Jan Hojn ý Nikola H ájková Krist ýna Němejcová Michaela Kendall B ártů Source Type: research
